# Abbisko Therapeutics Deepens R&D Collaboration with Lilly

- Link: https://www.thailand-business-news.com/pr-news/abbisko-therapeutics-deepens-rd-collaboration-with-lilly
- Published: 2026-06-24T08:00:00+07:00
- Author: PR Newswire

|   |

SHANGHAI, June 24, 2026 /PRNewswire/ — Abbisko Therapeutics Co., Ltd. ("Abbisko 
Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered
into a strategic research collaboration and license agreement with Eli Lilly and
Company ("Lilly"), a leading global pharmaceutical company. Under the agreement,
the two companies will collaborate on the discovery and development of innovative
medicines across multiple targets, advancing novel drug candidates with global potential.

By leveraging their respective strengths in drug discovery, research and development,
and global drug development, Abbisko and Lilly aim to accelerate the advancement
of innovative therapeutic programs and bring new treatment options to patients worldwide.

Under the terms of this agreement, Abbisko will utilize its early-stage drug discovery
platform, innovative R&D ecosystem, and extensive development expertise to conduct
discovery and early development activities for novel drug programs directed against
disease targets selected by Lilly. Abbisko will receive an upfront payment and is
eligible to receive development, regulatory and commercial milestone payments totaling
up to approximately  US$1.9 billion. In addition, Abbisko will be eligible to receive
tiered royalties based on annual net sales of products arising from this collaboration.

In 2022, Abbisko and Lilly entered into a global collaboration and exclusive license
agreement to collaborate on the discovery, development, and potential commercialization
of a novel small-molecule therapeutic.

Supported by its continually evolving drug discovery platform, extensive R&D experience
and proven execution capabilities, Abbisko has continued to expand its global partnership
network and accelerate the translation of scientific innovation into therapeutic
advances. This collaboration with Lilly is expected to advance multiple innovative
programs and further strengthen Abbisko’s global innovation strategy and long-term
value creation potential.

**About Abbisko Therapeutics**

Founded in April 2016, Abbisko Therapeutics Co., Ltd. (HKEX: 02256.HK), is an oncology-
focused biopharmaceutical company based in Shanghai that is dedicated to the discovery
and development of innovative medicines to treat unmet medical needs in China and
globally. Abbisko was established by a group of seasoned drug hunters with rich 
research & development and managerial expertise from top multinational pharmaceutical
companies. Since its founding, Abbisko Therapeutics has built an extensive pipeline
of innovative programs focused on precision oncology and immuno-oncology.

Please visit [www.abbisko.com](https://www.abbisko.com/) for more information.

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Abbisko Therapeutics Deepens R&D Collaboration with Lilly ](http://www.prnasia.com/story/archive/4990290_CN90290_0?rand=184833)